Diagnosis Value of Interoceptive EEG Indicators by Rectal Stimulation in DoC

NCT ID: NCT07208942

Last Updated: 2025-10-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

45 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-12-01

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study on the Significance and Value of Interoception-Related Indicators in the Classification of Patients with Disorders of Consciousness (DoC) via Rectal Stimulation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Disorders of Consciousness (DoC) represent one of the sequelae of severe brain injuries caused by a variety of etiologies, including traumatic brain injury, stroke, and cardiac arrest. They may also result from primary neurological damage or systemic diseases. In recent years, with the advancement and development of surgical techniques and intensive care practices, an increasing number of DoC patients have survived life-threatening severe brain trauma. The large population of DoC patients imposes substantial psychological stress and economic burden on healthcare systems, social welfare services, and patients' families. Accurate identification and classification of DoC patients constitute a crucial prerequisite for clinical treatment and care.

Behavioral assessment of consciousness is currently the most common method for classifying DoC patients and is of great importance for critically ill patients. However, some cases of covert consciousness are difficult to identify, and even professional medical caregivers may encounter assessment errors. Such errors can lead to deviations in the selection of treatment strategies and the evaluation of prognostic efficacy for these patients. Precise diagnosis and classification of DoC are critical for prognostic treatment, as they enable the development of more rational rehabilitation protocols for patients and contribute to improving their quality of life.

The Coma Recovery Scale-Revised (CRS-R) is a standardized behavioral tool for the diagnosis of DoC. It primarily assesses patients' behavioral responses elicited by external sensory stimuli. The scale comprises six subscales: Auditory, Visual, Motor, Oromotor, Communication, and Arousal. Each subscale has a specific scoring range, with a total possible score of 23. Different total scores allow for the classification of patients into three categories: Vegetative State/Unresponsive Wakefulness Syndrome (VS/UWS), Minimally Conscious State (MCS, further divided into MCS+ and MCS-), and Emergent Minimally Conscious State (eMCS). However, the diagnosis and classification of VS/UWS and MCS using this scale are particularly challenging. This is because patients at the boundary between these two categories often exhibit highly similar behavioral responses to external stimuli, with only subtle differences. Additionally, the responses of DoC patients to behavioral assessments may be mere low-level reflexes or lack conscious involvement, making it difficult to achieve precise classification of DoC patients based solely on behavioral assessments.

Interoception refers to the bidirectional communication between the brain and the body's internal organs. Signals from internal organs-such as those related to heartbeat, respiratory movements, and gastrointestinal peristalsis-are transmitted to the cerebral cortex (including the insula and motor cortex) via the autonomic nervous system. Conversely, these cortical regions regulate the activity of target organs through the sympathetic and parasympathetic nervous systems. Interoception is essential for the maintenance of bodily homeostasis. Furthermore, a growing body of evidence indicates that interoception is also involved in higher cognitive functions, such as memory formation, emotional processing, and even the construction of the sense of self. Compared with exteroceptive pathways, the ascending interoceptive pathways in DoC patients tend to remain relatively intact. Therefore, interoception-related indicators, as a complement to exteroceptive behavioral response indicators, hold significant clinical value for the precise assessment of DoC patients.

Research on interoception-related indicators has emerged as a novel field for the differential diagnosis of DoC patients. These indicators serve as a vital supplement to behavioral and imaging assessments. Moreover, their application requires patients to engage in active conscious participation and induce awareness, which means interoception-related indicators can undertake the assessment tasks typically performed by imaging techniques in a more cost-effective and convenient manner. Consequently, they have inevitably become a focus of research in the field of consciousness and consciousness assessment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Disorders of Consciousness

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Disorders of consciousness

Patients assessed as Minimally Conscious State plus/minus (MCS+/-) and Unresponsive Wakefulness Syndrome (UWS) using the Coma Recovery Scale-Revised (CRS-R).

Rectal Stimulation

Intervention Type DEVICE

The stimulation balloon was lubricated with paraffin oil and inserted until the distal end of the balloon was 10 cm from the anal verge, so as to eliminate the influence of different stimulation sites on the subjects.

At the start of stimulation, the dilatable balloon was rapidly inflated to 60/80 mL, with a stimulation duration of 150 milliseconds. Concurrently with stimulation, the onset time of stimulation was marked on the electroencephalogram (EEG), and the time window for cortical potentials evoked by rapid rectal balloon distension stimulation was recorded. During the experiment, 35 stimulations were administered to the subjects; however, the first and last stimulations were excluded due to setup issues with the precision inflation-deflation control device for the intestinal balloon. Each stimulation was delivered as a 150-millisecond inflation pulse, providing 35 identical rectal stimulations. The inter-stimulus interval was randomly set to 12 ± 4 seconds, and EEG signals were

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rectal Stimulation

The stimulation balloon was lubricated with paraffin oil and inserted until the distal end of the balloon was 10 cm from the anal verge, so as to eliminate the influence of different stimulation sites on the subjects.

At the start of stimulation, the dilatable balloon was rapidly inflated to 60/80 mL, with a stimulation duration of 150 milliseconds. Concurrently with stimulation, the onset time of stimulation was marked on the electroencephalogram (EEG), and the time window for cortical potentials evoked by rapid rectal balloon distension stimulation was recorded. During the experiment, 35 stimulations were administered to the subjects; however, the first and last stimulations were excluded due to setup issues with the precision inflation-deflation control device for the intestinal balloon. Each stimulation was delivered as a 150-millisecond inflation pulse, providing 35 identical rectal stimulations. The inter-stimulus interval was randomly set to 12 ± 4 seconds, and EEG signals were

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non-acute Disorders of Consciousness (DoC) (disease course ≥ 28 days).
* Aged 18 years or older.
* No symptoms of fever, infection, or other similar conditions within 15 days.
* No use of sedatives within 15 days.
* No use of any drugs that may alter gastrointestinal motility within 7 days prior to testing.
* Family members of participating patients have provided consent and signed the informed consent form.

Exclusion Criteria

* Patients with functional impairments caused by developmental psychiatric disorders or neurological diseases.
* Patients with untreated epilepsy.
* Untreated cerebral edema.
* Patients with unstable vital signs.
* A history of intestinal diseases.
* A history of abdominal surgery other than simple appendectomy or simple cholecystectomy.
* Organic diseases such as spinal cord injury, traumatic brain injury, and thyroid dysfunction.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Second People's Hospital of Hefei

UNKNOWN

Sponsor Role collaborator

YiLin Zhao

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

YiLin Zhao

PhD

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Second People's Hospital of Hefei

Hefei, Anhui, China

Site Status RECRUITING

Hangzhou Normal University

Hangzhou, Zhejiang, China

Site Status ENROLLING_BY_INVITATION

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

YiLin Zhao

Role: CONTACT

18850147114

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yinliang QI

Role: primary

131099359067

Haibo Di

Role: backup

13588859929

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20241009-2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.